Vijaypd CeuticalShare price, financial results, shareholding and management
- Market cap
- ₹133 cr
- Stock P/E
- 26.7peers 30.7
- Book value
- ₹26.9
- Price to book
- 2.54
- EV / operating profit
- 32.7
- Market cap to sales
- 1.33
- ROCE · FY26
- 11.3%
- ROE · FY26
- 11.8%
- ROE, 3-year average
- 21.5%
- Operating margin · FY26
- 4.7%peers 13.4%
- Sales growth, 3 years
- 25.2%
- Profit growth, 3 years
- 202.9%
- Debt to equity
- 0.70peers 0.51
- Borrowings
- ₹36.7 cr
- Interest cover
- 4.9×
- Cash from business / op. profit
- -188%
- Debtor days
- 115
- Pledged
- 0.00%
- Promoter holding
- 56.43%
- Change in promoter holding
- +0.18 pts
- Shareholders
- 380
- 52-week high / low
- ₹115 / ₹38
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Vijaypd Ceutical share price chart
Close on 19 Nov 2026 · +9.98% on the day · Vol 34,000
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- -18.7%
- 3 months
- +19.4%
- 6 months
- -24.9%
- 1 year
- +43.0%
- Since IPO
- +95.1%
- Traded a day, 20 days
- ₹0.55 cr
- Taken for delivery
- 89%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +0% | +6% |
| 3 years, a year | +25% | +203% |
| Latest half, H2 FY26 | -5% | +50% |
About Vijaypd Ceutical: business, products and customers
VijayPD Ceutical buys medicines and health products from drug makers and delivers them to chemist shops, clinics and nursing homes in Mumbai and other parts of Maharashtra. It is also building a plant to make drug ingredients, and its shares trade on NSE Emerge.
The business began as the partnership firm Vijay Pharma in 1971 and became a company in March 2024, taking over the distribution business of P.D. Doshi in April 2024. It stocks medicines, surgical items, over the counter and nutrition products and some consumer goods from more than 150 drug companies, holds them in warehouses in Mumbai, and delivers to chemists, doctors, clinics and nursing homes who order through apps or its salesmen.
As a wholesaler it records the full value of the medicines it resells, so sales are large against profit and the margin over purchase cost is a few percent. Money is tied up in stock and in credit given to chemists, funded largely by a bank cash credit line, and expired products come back from chemists to be returned to makers, which cost ₹5.8 cr in FY25. In FY26 income outside trading made up most of the year's profit before tax.
Read more about the business
The company is adding to its reach by buying other Mumbai distributors: 95% of Zen Pharmaceuticals in December 2025 and all of Siddharth Drugs in April 2026, both for cash, and it opened a distribution centre at Vikhroli in January 2026. Separately it is building a plant at MIDC Shrirampur in Ahmednagar district to make active pharmaceutical ingredients and intermediates, a business its promoters have not run before.
The offer document describes pharmaceutical distribution as highly competitive, with organised and unorganised rivals, many larger, and names none. Among listed companies, Entero Healthcare Solutions also distributes medicines to pharmacies and hospitals and grows by buying regional distributors, at a much larger scale.
From the offer document (prospectus, 2025), the annual report for FY26, the result filing of 1 July 2026 and the company's announcements of December 2025 to September 2026.
Read the deeper study ↓In its favour
- Sales have grown fast: 25% a year over three years.
To watch
- Completion of the drug ingredient plant at MIDC Shrirampur, due by March 2027 (Offer document, p.96 to 97).
- A definitive agreement or order following the August 2026 expression of interest for contract making (Announcement, 26 August 2026, p.1).
- First results including Siddharth Drugs, bought in April 2026 (Announcement, 8 April 2026, p.2 to 3).
- Whether the next auditor's report still finds a gap between bank statements and the books (Annual report FY26, p.57 to 58).
- Customers take longer to pay than before: 115 days in FY26, against 62 in FY23.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Vijaypd Ceutical revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were lower than in the same half a year before. Profit grew faster than sales.
Vijaypd Ceutical half-yearly results
SME companies report every six months · ₹ crore
| H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|
| Sales | 50.32 | 49.91 | 51.33 | 47.62 |
| Expenses | 44.84 | 46.99 | 46.97 | 47.27 |
| Operating profit | 5.48 | 2.92 | 4.36 | 0.35 |
| OPM | 10.9% | 5.8% | 8.5% | 0.8% |
| Interest | 1.17 | 0.98 | 1.06 | 0.53 |
| Depreciation | 0.30 | 0.31 | 0.28 | 0.34 |
| Profit before tax | 4.02 | 2.38 | 3.34 | 3.18 |
| Net profit | 2.95 | 1.76 | 2.42 | 2.64 |
Vijaypd Ceutical profit and loss
Full years to March, FY23 to FY26 · ₹ crore, consolidated where reported
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Sales | 51.09 | 59.15 | 100.22 | 100.23 |
| Expenses | 49.77 | 54.27 | 91.80 | 95.57 |
| Operating profit | 1.32 | 4.88 | 8.42 | 4.67 |
| OPM | 2.6% | 8.3% | 8.4% | 4.7% |
| Other income | 1.82 | 0 | 0.75 | 4.12 |
| Interest | 2.36 | 1.76 | 2.15 | 1.66 |
| Depreciation | 0.43 | 0.35 | 0.62 | 0.65 |
| Profit before tax | 0.35 | 2.77 | 6.40 | 6.47 |
| Tax rate | 48.6% | 40.4% | 26.4% | 22.7% |
| Net profit | 0.18 | 1.65 | 4.71 | 5 |
| EPS ₹ | · | · | 3.36 | 3 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% |
Vijaypd Ceutical profitability
Margins and returns on capitalLast year the company kept less from each rupee of sales than the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Operating margin | 2.6% | 8.3% | 8.4% | 4.7% |
| Tax rate | 48.6% | 40.4% | 26.4% | 22.7% |
| ROCE | · | 14.7% | 20.1% | 11.3% |
| ROE | · | 28.6% | 24.1% | 11.8% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% |
Vijaypd Ceutical debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It borrowed much more last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Vijaypd Ceutical balance sheet
At each 31 March · ₹ crore
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Equity capital | 0 | 1 | 14.03 | 19.53 |
| Reserves | 4.93 | 5.59 | 18.39 | 32.96 |
| Net worth | 4.93 | 6.59 | 32.42 | 52.48 |
| Borrowings | 25.57 | 24.45 | 21.77 | 36.71 |
| Other liabilities | 2.37 | 2.23 | 3.09 | 11.51 |
| Total liabilities | 32.87 | 33.27 | 57.28 | 100.70 |
| Fixed assets | 2.73 | 2.43 | 8.74 | 9.21 |
| Capital work in progress | 0 | 0 | 0.11 | 2 |
| Investments | 0.16 | 0.15 | 0.25 | 0.26 |
| Other assets | 29.98 | 30.69 | 48.18 | 89.23 |
| Receivables | · | · | · | 31.64 |
| Inventory | · | · | · | 12.46 |
| Cash | · | · | · | 17.52 |
| Trade payables | · | · | · | 8.15 |
Vijaypd Ceutical cash flow
₹ crore
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Cash from operations | 0.30 | 2.93 | -34.50 | -8.78 |
| Cash from investing | -0.09 | 12.78 | -9.72 | -13.33 |
| Cash from financing | -0.18 | -1.86 | 47.32 | 28.18 |
| Net cash flow | 0.03 | 13.85 | 3.10 | 6.07 |
| Capital spending | · | · | · | 2.67 |
Working capital
Days
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Debtor days | 62 | 69 | 87 | 115 |
| Inventory days | 31 | 29 | 48 | 50 |
| Days payable | 15 | 5 | 8 | 33 |
| Cash conversion cycle | 78 | 92 | 126 | 129 |
| Working capital days | -84 | -60 | 69 | 57 |
Vijaypd Ceutical peers and competitors
Listed SME companies in the same industryBy sales, Vijaypd Ceutical is number 24 of the 34 listed SME companies in electrical equipment.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Anawil Wire and Engineering | 1,069 | 28.9 | 143 | 37 | 43.0% | 1.42 |
| Eppeltone Engineers | 191 | 15.4 | 135 | 12.4 | 14.4% | 0.43 |
| Trom Industries | 55 | 8.0 | 123 | 6.9 | 8.5% | 0.59 |
| Saakshi Medtech and Panels | 666 | 55.5 | 116 | 12 | 19.0% | 0.23 |
| Vijaypd Ceutical | 133 | 26.7 | 100 | 5 | 4.7% | 0.70 |
| Akanksha Power and Infrastructure | 368 | 62.9 | 91.6 | 5.9 | 12.4% | 2.06 |
| Avana Electrosystems | 401 | 34.2 | 83.9 | 11.7 | 19.5% | 0.01 |
| Sungarner Energies | 74 | 19.3 | 74.2 | 3.8 | 11.1% | 1.81 |
| Accord Transformer & Switchgear | 232 | 51.5 | 70.1 | 4.5 | 10.0% | 0.18 |
| Jigar Cables | 59 | 32.5 | 57.9 | 1.8 | 5.8% | 0.39 |
| Vdeal System | 53 | 12.8 | 45.1 | 4.2 | 17.0% | 0.69 |
| Median of the 10 others | 212 | 30.7 | 87.7 | 6.4 | 13.4% | 0.51 |
Vijaypd Ceutical shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has grown a lot.
Vijaypd Ceutical shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 25 | Oct 25 | Mar 26 | |
|---|---|---|---|
| Promoters | 78.30% | 56.25% | 56.43% |
| Indian institutions (DIIs) | - | 0.00% | 0.72% |
| HNIs (over ₹2 lakh each) | 19.86% | 24.41% | 30.67% |
| Small holders (up to ₹2 lakh) | 0.64% | 14.59% | 9.10% |
| Companies and others | 1.20% | 4.75% | 3.08% |
| Number of shareholders | 46 | 442 | 380 |
The named holders are at 31 March 2026, beside 6 Oct 2025, each under the group the pattern files them in.
Vijaypd Ceutical study: the business from its own documents
Read from 3 of the company's own documentsVijaypd Ceutical so far
From the company's own record
- October 1971Company formed
- 7 Oct 2025Listed on NSE Emerge at ₹35
- 26 Aug 2026An order announced
- 31 March 2026Promoters at 56.43%
- 1 May 2026Highest close since listing, ₹104.21
Vijaypd Ceutical key facts from the filings
Each figure with the document it comes from
- Customers
- 2,109
- Chemists, clinics and nursing homes served at March 2025, up from 1,295 a year earlier; chemist shops gave 98.43% of FY25 revenue.Offer document, p.156 and p.158 to 159
- Largest customer
- 3.82%
- Share of FY25 revenue from the biggest customer; the top ten together gave 17.13%, so no single buyer matters much.Offer document, p.167
- Repeat business
- 80.08%
- Share of FY25 revenue from customers who had bought before.Offer document, p.160
- Other income
- ₹4.0 cr
- Income outside trading in FY26, against ₹0.75 cr in FY25, out of a profit before tax of ₹6.5 cr.Annual report FY26, p.31
- Ingredient plant
- ₹10.8 cr
- Issue money set aside for the drug ingredient plant on about 6,000 square metres at MIDC Shrirampur, due by March 2027; ₹2.3 cr had been used by March 2026.Offer document, p.93 and p.96 to 97; Result filing, 1 July 2026, p.6
Show 5 more facts
- Siddharth Drugs
- ₹7.0 cr
- Cash paid for all of this Mumbai drug distributor, which had sales of ₹51.0 cr in FY25.Announcement, 8 April 2026, p.2 to 3
- Zen Pharmaceuticals
- 95%
- Share bought in this distribution firm for ₹0.45 cr in December 2025; it had ₹6.4 cr of turnover in its latest reported period.Announcement, 1 December 2025, p.2; Annual report FY26, p.40
- Bank stock statements
- ₹15.7 cr gap
- Difference between stock and dues reported to the bank and the books for the March 2026 quarter, which the auditor said did not agree.Annual report FY26, p.57 to 58
- Issue costs
- ₹4.2 cr
- Spent on the October 2025 public issue, more than the ₹2.6 cr estimated in the prospectus; the issue raised ₹19.25 cr at ₹35 a share.Result filing, 1 July 2026, p.6; Offer document, p.106
- Ingredient export interest
- 3 products
- Sitagliptin, apixaban and rivaroxaban named in an expression of interest from Squadron Pharmaceuticals for contract making for export; terms not yet settled.Announcement, 26 August 2026, p.1
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company says the drug ingredient plant at MIDC Shrirampur is to be completed by March 2027, and its March 2026 filing describes the project as in progress, with unused issue money held in deposits. It has an expression of interest for contract making of three ingredients for export, a memorandum with Ann Finechem for ingredient supply, and a research tie up with Acute Research for process development and scale up. It gives no sales or profit guidance.
| What management said | When | What happened |
|---|---|---|
| Issue expenses of ₹2.6 cr | Prospectus, September 2025 | ₹4.2 cr spent on the issue |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
VijayPD Ceutical earns a small margin on every medicine it buys from drug makers and resells to chemists, so it needs high volumes and tight control of stock and credit.
Its weak spots are thin margins, cash tied up in stock and dues, a plant in a business it has never run, and gaps the auditor found in what it reported to its bank.
WatchCan it set its own prices?It resells other companies' medicines at prices and margins largely set by the makers and by rival wholesalers.
WatchHow strong is it against rivals?Many distributors, several larger and better funded, compete for the same chemists.
StrongWho are its customers?Thousands of chemist shops, with no single buyer large enough to hurt if it left.
WatchDoes it need a lot of money?Stock and credit to chemists tie up cash, the bank funds much of it, and the new plant needs more.
AverageCan it keep finding new work?It keeps adding chemists and buying smaller distributors, but the drug ingredient business has no signed customer yet.
AverageDo good and bad years swing a lot?People need medicines in every year, but expired stock and the cost of carrying it can move profit sharply.
Who runs Vijaypd Ceutical?
Promoters, directors and officers; tap a name for the background
SMSamit Madhukar ShahPromoter, Chairman and Managing Director · holds 4.52%
Holds an MBA in business finance from the University of Lincolnshire and Humberside (2000) with more than 24 years in pharmaceutical distribution. Oversees operations and leads expansion and acquisitions.
Offer document, p.186 and p.188; Shareholding pattern, March 2026BDBhavin Dhirendra ShahPromoter and Whole Time Director · holds 8.38%
Holds a Bachelor of Commerce from the University of Mumbai (2005) with more than 19 years in the business; runs the distribution network and day to day operations.
Offer document, p.186 and p.188; Shareholding pattern, March 2026RJRahul Jitendra ShahPromoter and Whole Time Director
Holds a Master of Commerce from the University of Mumbai (2005). With the business as dispatch manager since May 2001, in charge of delivery partners, dispatch and stock levels; Whole Time Director since June 2025.
Offer document, p.188 and p.192NNNarendra Nagindas ShahPromoter and Non-Executive Director · holds 8.14%
A founder member, associated with Vijay Pharma for 53 years; passed the secondary school examination in 1970. The offer document records Jigar Narendra Shah, a promoter group shareholder, as a son of Narendra Nagindas Shah.
Offer document, p.188 to 189; Shareholding pattern, March 2026VDVasanti Dhirendra ShahPromoter · holds 16.47%
Named in the offer document as instrumental in founding and growing the business; does not take part in day to day operations.
Offer document, p.201; Shareholding pattern, March 2026DMDina Madhukar ShahPromoter · holds 8.60%
A founding member who completed the pre-university examination at SNDT Women's University in 1967; does not take part in day to day operations.
Offer document, p.201; Shareholding pattern, March 2026HJHemanti Jitendra ShahPromoter · holds 5.44%
Named in the offer document as instrumental in founding and growing the business; does not take part in day to day operations.
Offer document, p.202; Shareholding pattern, March 2026CKChirag K ThakkarChief Financial Officer
A Chartered Accountant (2020) with a Bachelor of Commerce from the University of Mumbai, earlier a senior associate at C.J. Mehta & Co for over ten years; CFO since May 2025.
Offer document, p.197; Annual report FY26, p.4NHNikita H PedhdiyaIndependent Director
A practising Company Secretary since 2015 with commerce and law degrees from the University of Mumbai and more than 15 years in secretarial, legal and listing compliance.
Offer document, p.188Vijaypd Ceutical latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹47.6 cr (-5%), net profit ₹2.6 cr (+50%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 56.25% to 56.43%.
- 26 Aug 2026: an order announced.
Vijaypd Ceutical announcements
38 on record, latest first; each opens the filing on the exchange
- Quarterly Compliance Report on Corporate governance - within 21 days from the enVijaypd Ceutical Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the 30th September, 2026PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- General UpdatesAppointment of Investor Relations (IR) agencyPDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 30, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Updates'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Technical Business Collaboration with Acute ResearPDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 30, 2026PDF ↗
- Outcome of Board MeetingHeld on August 29, 2026PDF ↗
- Updates'Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Receipt of Expression of Interest for API ContPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
Vijaypd Ceutical annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
Vijaypd Ceutical share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Vijaypd Ceutical's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,95,28,686 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY23 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Vijaypd Ceutical
What does Vijaypd Ceutical do?
VijayPD Ceutical buys medicines and health products from drug makers and delivers them to chemist shops, clinics and nursing homes in Mumbai and other parts of Maharashtra. It is also building a plant to make drug ingredients, and its shares trade on NSE Emerge.
What is the share price of Vijaypd Ceutical?
₹68.3 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Vijaypd Ceutical?
₹133 cr at the close on 19 Nov 2026, on 1,95,28,686 shares.
What is the P/E of Vijaypd Ceutical?
26.7 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Vijaypd Ceutical's revenue and profit?
Revenue ₹100 cr and profit after tax ₹5 cr in FY26.
Who are the promoters of Vijaypd Ceutical?
Samit Madhukar Shah, Bhavin Dhirendra Shah, Rahul Jitendra Shah, Narendra Nagindas Shah, Vasanti Dhirendra Shah, Dina Madhukar Shah, Hemanti Jitendra Shah; promoters held 56.43% at 31 March 2026.
What was the IPO price of Vijaypd Ceutical?
₹35 a share; it listed on 7 Oct 2025.
What is Vijaypd Ceutical's website?
www.vijaypdceutical.com
More SME companies like Vijaypd Ceutical
Other listed SME companies in electrical equipment, the closest in size first, each read from its own documents.
- Eppeltone EngineersEEPL · NSE Emerge · Electrical Equipment · listed 2025Market cap ₹150 cr
- Smarten Power SystemsSMARTEN · NSE Emerge · Electrical Equipment · listed 2025Market cap ₹153 cr
- G V ElectricalsGVELECTRIC · BSE SME · Electrical EquipmentMarket cap ₹116 cr
- Shivalic Power ControlSPCL · NSE Emerge · Electrical Equipment · listed 2024Market cap ₹110 cr
- Sahaj SolarSAHAJSOLAR · NSE Emerge · Electrical Equipment · listed 2024Market cap ₹169 cr
- Accord Transformer & SwitchgearACCORDTS · BSE SME · Electrical EquipmentMarket cap ₹180 cr
Every listed SME company in Electrical Equipment → · SME companies listed in 2025 →
Built from 1 offer document, 1 result filing, 1 annual report, 38 exchange announcements, 3 shareholding patterns and 4 years of reported results. Every figure carries its source; where the documents are silent, the page says so.